Colinz Laboratories Ltd. is an Indian pharmaceutical company categorized under the **MSME (Micro, Small, and Medium Enterprises) sector**. The company specializes in the manufacturing and marketing of pharmaceutical formulations, with a primary strategic focus on the **gynaecological sector**. Operating within a single reportable business and geographical segment, the company has built a reputation for producing high-quality **off-patented products**, utilizing innovation to extend market shelf life and maintain a competitive edge in a highly fragmented domestic market. --- ### **Strategic Pivot: Asset Monetization & Infrastructure Modernization** Colinz Laboratories is currently undergoing a transformative restructuring phase. Management has determined that its legacy infrastructure is no longer viable under evolving regulatory frameworks. Consequently, the company is transitioning from its 25-year-old manufacturing base to a more modern, compliant operational model. #### **The Slump Sale Strategy** To optimize the balance sheet and exit non-compliant facilities, the company has secured shareholder approval to dispose of its primary undertakings on a **slump sale basis**. | Asset Category | Location | Status | Consideration | | :--- | :--- | :--- | :--- | | **Factory Undertaking** | Plot No 60, STICE, Sinnar, Nashik | **Approved for Sale** (Jan 2026) | **Rs. 4.00 Crore** | | **Office Premises** | A-101 to A-103, Pratik Estate, Mumbai | **Approved for Disposal** (Oct 2025) | Min. **Rs. 3.00 Crore** | * **Transaction Details:** The factory sale to **M/s. Hilsun Foods And Drugs Private Limited** includes land, buildings, and machinery but specifically **excludes the Brand name** and related intangible assets, which Colinz retains. * **Rationale for Exit:** The existing Sinnar facility requires "huge expenditure" to meet the **revised Schedule M-WHO Norms**. Management concluded that overhauling the 25-year-old site was less cost-effective than a total relocation. #### **Future Manufacturing Roadmap** The Board is evaluating two primary paths to achieve **WHO GMP certification**, which is essential for their goal of entering **global export markets**: 1. Constructing a **greenfield manufacturing facility** in **Gujarat** with incremental capital expenditure. 2. Acquiring an **existing, "readymade" factory** that already complies with the revised **WHO norms** and regulatory requirements. --- ### **Financial Performance & Capital Structure** Despite inflationary pressures and muted demand in the MSME sector, the company maintains a stable financial profile characterized by a **debt-free balance sheet**. #### **Key Financial Metrics** | Metric | FY 2023-24 (₹ in Lacs) | FY 2022-23 (₹ in Lacs) | | :--- | :--- | :--- | | **Total Revenue** | **730.46** | **732.70** | | **Revenue from Operations** | **702.96** | **705.20** | | **Profit Before Tax (PBT)** | **65.03** | **59.98** | | **Net Profit (After Tax)** | **48.67** | **45.74** | | **Total Comprehensive Income** | **80.97** | **45.74** | * **Capital Allocation:** The Board has opted **not to recommend a dividend**, choosing instead to **plough back surpluses** into the business to fund the upcoming manufacturing transition. * **Equity Structure:** Following the forfeiture of **2,051,900** equity shares in 2023, the total paid-up capital stands at **Rs. 25,19,100**. * **Dematerialization:** **72.98%** of the company’s shares are held in dematerialized form. --- ### **Ownership & Governance Evolution** The company has seen significant changes in its leadership and shareholding structure following the demise of promoter Dr. Mani L.S. * **Promoter Transmission:** In late 2025, **8,67,750** equity shares (**34.45%** of paid-up capital) were transmitted to **Mrs. Vijaya Mani**, increasing her individual stake from **15.11%** to **49.56%**. * **Leadership:** CEO **Mr. Narayan Kutty Menon** has been granted executive authority to lead the asset divestment process. * **Board Oversight:** To ensure robust governance during the restructuring, the company appointed **CA Mr. Bhavik Ashokkumar Shah** and **Mr. Baptist Bernard Dias** as Independent Directors in August 2024 for **5-year terms**. --- ### **Market Dynamics & Risk Landscape** Colinz Laboratories operates in an environment characterized by intense competition and stringent price controls. #### **Operational Risks** * **Market Fragmentation:** The company competes against over **20,000 players**, ranging from small MSMEs to large domestic and foreign multinationals. * **Pricing Pressures:** Significant headwinds from government initiatives such as **Jan Aushadhi Stores** and **Ayushman Bharat**, which provide medicines at "rock bottom" prices. * **Regulatory Controls:** Exposure to the **Drugs Price Control Order (DPCO)**, which imposes price ceilings on both scheduled and non-scheduled formulations. #### **Risk Management Framework** The company maintains a formal framework governed by a **Business Risk Management Committee** under **Regulation 21 of SEBI (LODR) Regulations**. | Risk Category | Status / Mitigation | | :--- | :--- | | **Litigation Risk** | **Zero** pending litigations impacting financial position. | | **Liquidity Risk** | No material uncertainty in meeting liabilities due within **1 year**. | | **Ethical Risk** | **Zero Tolerance** policy against bribery; mandatory integrity training. | | **Compliance Risk** | **100% Compliance** with Director qualifications under **Section 164(2)**. | --- ### **Operational Infrastructure Summary** * **Registered Office:** A-101, Pratik Estate, Next to Shakticard, Mulund-Goregaon Link Road, Mumbai - 400 078. * **Current Factory:** Plot No. **60, STICE**, Sinnar-Shirdi Road, Musalgaon, Sinnar, Dist. **Nasik - 422 103**. * **Regulatory Environment:** Operations are strictly governed by the **Drugs and Cosmetics Act (1940)**, Legal Metrology Act, and SEBI guidelines. * **Subsidiaries:** The company has **no subsidiaries** and no outstanding capital commitments as of August 2025.